Trade Haven Hub - Investing and Stock News
  • Investment Tips
  • Trade Tips
  • Crypto News
  • Economy News
  • Stock Market
  • Investment Tips
  • Trade Tips
  • Crypto News
  • Economy News
  • Stock Market
No Result
View All Result
Trade Haven Hub - Investing and Stock News
No Result
View All Result
Home Trade Tips

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

admin by admin
June 4, 2025
in Trade Tips
0
Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Phase 1 1 First-In-Human study designed to assess safety   ,   tolerability   , right dose for Phase 2 and early signs of efficacy   of 177Lu-RAD20   2   in individuals with   advanced HER2-positive solid   tumors

Previous clinical proof-of concept data 2 for targeting HER-2 demonstrated the safety and biodistribution of 99mTc-RAD202 in humans

Radiopharm Theranostics (ASX:RAD, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its Phase 1 ‘HEAT’ clinical trial of RAD202, a proprietary nanobody that targets Human Epidermal Growth Factor Receptor 2 (HER2)-positive expression in a wide array of advanced solid tumors.

The open-label Phase 1 ‘HEAT’ clinical trial is a dose escalation trial of 177Lu-RAD202 that is designed to determine the recommended Phase 2 dose and to evaluate the safety and preliminary clinical activity of this novel radiotherapeutic in individuals with HER2-expressing advanced cancers. The study is currently being conducted at clinical centers across Australia.

‘Dosing patients in the HEAT clinical trial marks an important milestone in our transition to a clinical-stage company,’ said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. ‘Despite progressive improvements in the management of metastatic HER2-positive disease, the majority of patients experience disease progression on current standard of care and require further therapeutic options. The dosing of the first patient in the ‘HEAT’ trial represents a significant step toward achieving RAD202’s potential to address an unmet need for HER2-positive metastatic patients who are progressing or unable to tolerate current treatment options. With RAD202, we hope to provide an option that can meaningfully improve clinical outcomes for HER2-positive patients, while preserving their quality of life.’

HER2 is overexpressed in breast cancer as well as several other solid tumors and represents a validated target in oncology. RAD202 is a proprietary single domain antibody that targets HER2. Ten HER2-positive breast cancer patients previously dosed in a Phase 1 diagnostic study of RAD202 demonstrated clinical proof-of concept as well as the safety and biodistribution of RAD202, validating its potential for the treatment of advanced HER2-expressing cancers 2 . Preclinical findings 3 examining the therapeutic effect in HER2-positive xenografts were also recently reported with 177Lu-RAD202. Collectively, these data further justify first in humans dose finding studies.

‘It is a privilege to be the first centre to administer 177Lu-RAD202, targeting HER2-positive tumors in this Phase 1 clinical trial (HEAT).’ said Dr Aviral Singh, Clinical Head of Theranostics and Nuclear Medicine at St John of God Murdoch Hospital. ‘This opens the possibility of novel therapeutic avenues for patients with aggressive tumor types, including breast, ovarian, gastric, pancreatic, bladder, and several other cancers. With the trust put in us by Radiopharm, we look forward to a successful trial with beneficial outcomes for our patients.’

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com .

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (Formerly Stern IR)
E: annemarie.fields@precisionaq.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

________________________________

1 clinicaltrials.gov/study/NCT06824155
2 Zhao et al, Molecular Pharmaceutics 2021 18 (9), 3616-3622
3 Altunay B. et al, EP-0136, Eur J Nucl Med Mol Imaging (2024) 51 (Suppl 1): S1–S1026. DOI: 10.1007/s00259-024-06838-z

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com
Previous Post

LaFleur Minerals Provides Swanson Gold Deposit and Beacon Mill Restart Update to Produce Gold and Announces Investor Call on June 5

Next Post

Charbone Hydrogene a execute un financement de 50 millions USD pour accelerer son expansion en hydrogene en Amerique du Nord, facilite par US Capital Global

Next Post
Charbone Hydrogene a execute un financement de 50 millions USD pour accelerer son expansion en hydrogene en Amerique du Nord, facilite par US Capital Global

Charbone Hydrogene a execute un financement de 50 millions USD pour accelerer son expansion en hydrogene en Amerique du Nord, facilite par US Capital Global

  • Trending
  • Comments
  • Latest
Pepe Price Climbs 43% With Only 21 Days Left to Buy MIND of Pepe Cheap, Nearly $9m Raised 

Pepe Price Climbs 43% With Only 21 Days Left to Buy MIND of Pepe Cheap, Nearly $9m Raised 

May 9, 2025
Bitcoin Price Prediction: At $103,688 BTC Shows Unstoppable Weekly Growth of 7.6% – Could We See a New All-Time High Before June?

Bitcoin Price Prediction: At $103,688 BTC Shows Unstoppable Weekly Growth of 7.6% – Could We See a New All-Time High Before June?

May 10, 2025
Murchison South Increases to 67koz Gold Across Two Pits

Murchison South Increases to 67koz Gold Across Two Pits

May 13, 2025
Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout, pulls outlook

Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout, pulls outlook

May 8, 2025
US Seeks to Seize $7.7M in Crypto Linked to North Korean IT Worker Fraud Ring

US Seeks to Seize $7.7M in Crypto Linked to North Korean IT Worker Fraud Ring

0
Quantum Computing: its Evolution and its Potential Future

Quantum Computing: its Evolution and its Potential Future

0
Quantum Computing: its Evolution and its Potential Future

Quantum Computing: its Evolution and its Potential Future

0
Air Direct Capture – Reducing CO2 from the Atmosphere

Air Direct Capture – Reducing CO2 from the Atmosphere

0
US Seeks to Seize $7.7M in Crypto Linked to North Korean IT Worker Fraud Ring

US Seeks to Seize $7.7M in Crypto Linked to North Korean IT Worker Fraud Ring

June 6, 2025
Hong Kong Stablecoin Regulations to Take Effect August 1 – Here’s What Changes

Hong Kong Stablecoin Regulations to Take Effect August 1 – Here’s What Changes

June 6, 2025
Justin Huhn: Uranium Game On — Supply “Mirage,” De-risked Demand, Next Price Move

Justin Huhn: Uranium Game On — Supply “Mirage,” De-risked Demand, Next Price Move

June 6, 2025
Crypto Trader James Wynn Confesses He ‘Lost Control’ After Losing $100M in a Month

Crypto Trader James Wynn Confesses He ‘Lost Control’ After Losing $100M in a Month

June 6, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent News

    US Seeks to Seize $7.7M in Crypto Linked to North Korean IT Worker Fraud Ring

    US Seeks to Seize $7.7M in Crypto Linked to North Korean IT Worker Fraud Ring

    June 6, 2025
    Hong Kong Stablecoin Regulations to Take Effect August 1 – Here’s What Changes

    Hong Kong Stablecoin Regulations to Take Effect August 1 – Here’s What Changes

    June 6, 2025
    Justin Huhn: Uranium Game On — Supply “Mirage,” De-risked Demand, Next Price Move

    Justin Huhn: Uranium Game On — Supply “Mirage,” De-risked Demand, Next Price Move

    June 6, 2025
    Crypto Trader James Wynn Confesses He ‘Lost Control’ After Losing $100M in a Month

    Crypto Trader James Wynn Confesses He ‘Lost Control’ After Losing $100M in a Month

    June 6, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 tradehavenhub.com | All Rights Reserved

    No Result
    View All Result
    • Investment Tips
    • Trade Tips
    • Crypto News
    • Economy News
    • Stock Market

    Copyright © 2025 tradehavenhub.com | All Rights Reserved